Sarepta Therapeutics, Inc. (SRPT) News
Track canonical SquawkNews coverage tagged to SRPT, Sarepta Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 27 indexed stories across 14 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Sarepta Therapeutics, Inc. (SRPT) Reports 2-Year Functional Benefit for ELEVIDYS in Older DMD Patients
Sarepta Therapeutics reported that ELEVIDYS showed durable, nominally statistically significant functional benefits over two years vs external controls in ambulatory DMD patients aged 8—12, with manageable safety. Separa
NEWS | Sep 30, 2026, 12:31 PM UTC
H
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual Congress of the World Muscle Society (WMS) that provide evidence of clinic
GEOPOLITICS | Sep 30, 2026, 12:30 PM UTC
H
Weekly Recap: REGENXBIO and UPenn settlement and $39M payment to Regenxbio
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) paid $39M to settle patent suits with REGENXBIO and UPenn, securing releases and AAVrh74/ELEVIDYS covenants and dismissing litigation, while preparing late—breaking ELEVIDYS effic
NEWS | Sep 28, 2026, 11:05 AM UTC
H
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31st Annual Congress of
GEOPOLITICS | Sep 25, 2026, 12:30 PM UTC
L
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting, taking place Sept. 25-27
NEWS | Sep 24, 2026, 12:30 PM UTC
L
Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
REGENXBIO Inc. NASDAQ:RGNX
NEWS | Sep 23, 2026, 09:09 PM UTC
L
Sarepta Therapeutics Settles AAVrh74 Patent Disputes With REGENXBIO and UPenn for $39 Million
Sarepta Therapeutics entered into a settlement agreement with REGENXBIO and the University of Pennsylvania to resolve patent disputes related to AAVrh74-based gene therapies, including ELEVIDYS. Sarepta will pay a $39 mi
NEWS | Sep 23, 2026, 08:24 PM UTC
L
Sarepta Therapeutics, Inc.: Regenxbio and UPenn Agreed not to sue Sarepta or Catalent>SRPT
Sarepta Therapeutics, Inc.: Regenxbio and UPenn Agreed not to sue Sarepta or Catalent>SRPT
NEWS | Sep 23, 2026, 08:23 PM UTC
L
Sarepta Therapeutics, Inc.: To Pay Regenxbio $39M Within Ten Days of the Effective Date of the Settlement Agreement >SRPT
Sarepta Therapeutics, Inc.: To Pay Regenxbio $39M Within Ten Days of the Effective Date of the Settlement Agreement >SRPT
NEWS | Sep 23, 2026, 08:22 PM UTC
L
Sarepta Therapeutics, Inc.: Settlement Regards, Among Other Matters, Resolution of Pending Patent Infringement Litigations >SRPT
Sarepta Therapeutics, Inc.: Settlement Regards, Among Other Matters, Resolution of Pending Patent Infringement Litigations >SRPT
NEWS | Sep 23, 2026, 08:18 PM UTC
L
Sarepta Therapeutics, Inc.: Entered Settlement Agreement With Regenxbio, UPenn Trustees, and Catalent >SRPT
Sarepta Therapeutics, Inc.: Entered Settlement Agreement With Regenxbio, UPenn Trustees, and Catalent >SRPT
NEWS | Sep 23, 2026, 08:18 PM UTC
M
Dyne and Sarepta shares slump as Novartis trial setback hits muscle disease stocks
Shares of Dyne Therapeutics (DYN) and Sarepta (SRPT) fell Tuesday after Novartis’ NOT treatment for a muscle-wasting disorder failed in a trial, raising concerns about similar therapies for a rare disease.
EQUITY | Sep 08, 2026, 05:00 PM UTC
L
Sarepta Therapeutics names Route 79 scholarship recipients for 2026-2027
Sarepta Therapeutics announced recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 academic year.
EQUITY | Sep 08, 2026, 01:08 PM UTC
L
Sarepta names 25 Route 79 scholarship recipients for 2026-2027
Sarepta Therapeutics announced 25 recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 academic year, including 20 awards for individuals living with Duchenne.
EQUITY | Sep 08, 2026, 01:01 PM UTC
L
SRPT - Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
SRPT - Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
EQUITY | Aug 31, 2026, 08:34 PM UTC
L
Sarepta Therapeutics to Present at Morgan Stanley Global Healthcare Conference
Sarepta Therapeutics announced it will present at the Morgan Stanley 24th Annual Global Healthcare Conference.
EQUITY | Aug 31, 2026, 08:30 PM UTC
L
SRPT seen on track for best week in five months
TradingView News says SRPT is on track for its best week in five months, ahead of late-2026 clinical data.
EQUITY | Aug 27, 2026, 07:01 PM UTC
L
Near 200dma support LIN KKR OGE MCK STE APG MLI WRB FHB GMED SRPT UTHR GNRC GNTX CMI RITM WTM RMD WFRD
Near 200dma support LIN KKR OGE MCK STE APG MLI WRB FHB GMED SRPT UTHR GNRC GNTX CMI RITM WTM RMD WFRD
EQUITY | Aug 20, 2026, 07:27 PM UTC
L
SRPT - Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
SRPT - Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
EARNINGS | Aug 05, 2026, 08:20 PM UTC
L
SRPT - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRPT - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EQUITY | Jul 29, 2026, 09:05 PM UTC
L
SRPT Sarepta Therapeutics appoints Michael severino, M.D., Chief Executive Officer Sarepta Therapeutics - Doug ingram to retire and serve as
SRPT Sarepta Therapeutics appoints Michael severino, M.D., Chief Executive Officer Sarepta Therapeutics - Doug ingram to retire and serve as advisor until end of 2026
EQUITY | Jul 27, 2026, 12:35 PM UTC
L
SRPT appoints Michael Severino as CEO.
SRPT appoints Michael Severino as CEO.
EQUITY | Jul 27, 2026, 12:34 PM UTC
L
SRPT Reiterate Sell, $14 PT – expect continued headwinds for exondys and elevidys @ DBAB
SRPT Reiterate Sell, $14 PT – expect continued headwinds for exondys and elevidys @ DBAB
EQUITY | Jul 27, 2026, 12:19 PM UTC
L
Tractor Supply downgrade, Five Below upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: Mizuho upgraded Five Below (FIVE)
EQUITY | Jul 09, 2026, 01:47 PM UTC
H
Sarepta price target lowered to $20 from $23 at Piper Sandler
Piper Sandler lowered the firm's price target on Sarepta to $20 from $23 and keeps a Neutral rating on the shares. The firm lowers its Q2 Elevidys U.S. revenue estimate to $93M from $102.9M and collaboration revenue to $
EQUITY | Jul 09, 2026, 11:15 AM UTC
L
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs
The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.’s (NASDAQ: SRPT ) supplemental New Drug Applications seeking to convert the accelerated approvals of AMONDYS 45 (casimersen) and V
GEOPOLITICS | Jun 30, 2026, 04:44 PM UTC
L
Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action D
Accepted for review with target action date of February 28, 2027 Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Adminis
REGULATION | Jun 30, 2026, 12:38 PM UTC